酸苄酚宁 | 7181-73-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 酸苄酚宁
• 英文名称: bephenium
• 英文别名: bephenium hydroxynaphthoate；ZINC00001023；benzyldimethyl(2-phenoxyethyl)ammonium；Benzyl-dimethyl-<2-(2-methyl-phenoxy)-aethyl>-ammonium；Benzyl-dimethyl->2-(2-methyl-phenoxy)-aethyl>-ammonium；Benzyl-dimethyl-(2-phenoxy)-aethyl-ammonium；benzyl-dimethyl-(2-phenoxyethyl)azanium
• CAS: 7181-73-9
• 化学式: C₁₇H₂₂NO
• 分子量: 256.368
• InChiKey: AVWWVJUMXRXPNF-UHFFFAOYSA-N

物化性质

• 溶解度：
  溶于二甲基亚砜
• 稳定性/保质期：
  STABLE IN LIGHT & IN AIR /HYDROXYNAPHTHOATE SALT/
• 碰撞截面：
  162.3 Ų [M]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards]

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

ADMET

毒理性

• 人类毒性摘录

由于其苦味，该药物可能会引起恶心和呕吐...偶尔它可能会导致轻微和暂时的腹泻。/羟基萘甲酸盐；口服给药/

BECAUSE OF ITS BITTER TASTE, DRUG MAY PROVOKE NAUSEA & VOMITING... OCCASIONALLY IT MAY CAUSE MILD & TEMPORARY LOOSENESS OF STOOL. /HYDROXYNAPHTHOATE SALT; ORAL ADMIN/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 非人类毒性摘录

流涎、呕吐和腹泻在狗身上已被注意.../给予贝芬铵/

SALIVATION, VOMITING & DIARRHEA HAVE BEEN NOTED IN DOG.../GIVEN BEPHENIUM/

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

在给予治疗剂量的羟萘酸苯丙胺后，不超过0.5%在24小时内通过尿液排出。/羟萘酸/

AFTER ORAL ADMIN OF THERAPEUTIC DOSE OF BEPHENIUM HYDROXYNAPHTHOATE NOT MORE THAN 0.5% IS EXCRETED IN URINE WITHIN 24 HR. /HYDROXYNAPHTHOATE/

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

通常不从胃肠道吸收，但如果肠道发炎，一些药物可能会被吸收...通过尿液排出。/人类，口服/

NOT ORDINARILY ABSORBED FROM GI TRACT, BUT IF INTESTINES ARE INFLAMED, SOME DRUG MAY BE ABSORBED...EXCRETED IN URINE. /HUMAN, ORAL/

来源:Hazardous Substances Data Bank (HSDB)

安全信息

• 储存条件：
  2-8℃

制备方法与用途

生物活性

Bephenium 是一种用于钩虫感染和蛔虫病研究的驱虫剂，同时也是 B 型乙酰胆碱受体 (B-type AChR) 的激活剂。

化学性质

这类季铵盐包括羟萘酸苄酸宁、丙羟萘酸苄酚宁、氯化苄酚宁、溴化苄酚宁和碘化苄酚宁等。灭虫宁（羟萘酸苄酚宁）是一种黄绿色结晶性粉末，熔点为170-171℃，略溶于乙醇而不溶于醚，无臭且味道苦涩。

用途

Bephenium 是广谱抗肠虫药，对钩虫、蛔虫和鞭虫病均有效。其对抗钩虫的效果最佳，疗效优于四氯乙烯和溴萘酚，服药后三天内的排虫率为87.8%。然而，这类季铵化合物在肠道内的吸收较差，口服毒性较低，临床反应多为胃肠道刺激症状，如恶心、呕吐、腹痛和腹泻等。由于季铵类药物的不良反应较多且严重，它们已逐渐被甲苯咪唑和噻嘧啶等替代。灭虫宁片剂曾是卫生部1982年公布的127种被淘汰药品之一。

生产方法

Bephenium 由苯酚经缩合、胺化、季铵盐生成以及置换反应而制得。

文献信息

• SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME
  申请人：BlinkBio, Inc.

  公开号：US20170202970A1

  公开（公告）日：2017-07-20

  Described herein are silicon based conjugates capable of delivering one or more payload moieties to a target cell or tissue. Contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that permits accumulation of the conjugate within a target cell or tissue, one or more payload moieties (e.g., a therapeutic agent or imaging agent), and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.

  本文描述了基于硅的共轭物，能够将一个或多个有效载荷基团传递到靶细胞或组织。考虑到的共轭物可能包括一个硅-杂原子核心，一个或多个可选的催化基团，一个定位基团，允许共轭物在靶细胞或组织内积累，一个或多个有效载荷基团（例如，治疗剂或成像剂），以及与硅-杂原子核心共价结合的两个或更多个不干扰基团。
• ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF
  申请人：Meng Charles Q.

  公开号：US20140142114A1

  公开（公告）日：2014-05-22

  The present invention relates to novel anthelmintic compounds of formula (I) below: wherein Y and Z are independently a bicyclic carbocyclic or a bicyclic heterocyclic group, or one of Y or Z is a bicyclic carbocyclic or a bicyclic heterocyclic group and the other of Y or Z is alkyl, alkenyl, alkynyl, cycloalkyl, phenyl, heterocyclyl or heteroaryl, and variables X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 and X 8 are as defined herein. The invention also provides for veterinary compositions comprising the anthelmintic compounds of the invention, and their uses for the treatment and prevention of parasitic infections in animals.

  本发明涉及以下式（I）的新型驱虫化合物： 其中 Y和Z分别是双环碳环或双环杂环基团，或者Y或Z中的一个是双环碳环或双环杂环基团，另一个是烷基，烯基，炔基，环烷基，苯基，杂环基或杂芳基，以及变量X 1 ，X 2 ，X 3 ，X 4 ，X 5 ，X 6 ，X 7 和X 8 如本文所定义。本发明还提供了包含本发明的驱虫化合物的兽药组合物，以及它们用于治疗和预防动物寄生虫感染的用途。
• [EN] ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS<br/>[FR] COMPOSÉS DEPSIPEPTIDIQUES ANTHELMINTHIQUES
  申请人：MERIAL INC

  公开号：WO2018093920A1

  公开（公告）日：2018-05-24

  The present invention provides cyclic depsipeptide compounds of formula (I) wherein the stereochemical configuration of at least one carbon atom bearing the groups Cy1, Cy2, R1, R2, R3, R4, Ra and Rb is inverted compared with the naturally occurring cyclic depsipeptide PF1022A. The invention also provides compositions comprising the compounds that are effective against parasites that harm animals. The compounds and compositions may be used for combating parasites in or on mammals and birds. The invention also provides for an improved method for eradicating, controlling and preventing parasite infestation in birds and mammals.

  本发明提供了公式（I）的环状脱氨肽化合物，其中至少一个碳原子的立体化学构型与自然存在的环状脱氨肽PF1022A的基团Cy1、Cy2、R1、R2、R3、R4、Ra和Rb相比发生了倒置。该发明还提供了包含这些化合物的组合物，对危害动物的寄生虫具有有效性。这些化合物和组合物可用于对抗哺乳动物和鸟类体内或体表的寄生虫。该发明还提供了一种改进的方法，用于根除、控制和预防鸟类和哺乳动物的寄生虫感染。
• FUSED BICYCLIC HETEROCYCLE DERIVATIVES AS PESTICIDES
  申请人：Bayer Aktiengesellschaft

  公开号：US20200383334A1

  公开（公告）日：2020-12-10

  The invention relates to novel compounds of the formula (I) in which Aa, Ab, Ac, Ad, Q, R 1 and n have the definitions given above, to their use as acaricides and/or insecticides for controlling animal pests and to processes and intermediates for their preparation.

  这项发明涉及公式（I）的新化合物， 其中Aa、Ab、Ac、Ad、Q、R1和n具有上述给定的定义， 以及它们作为杀螨剂和/或杀虫剂用于控制动物害虫的用途，以及用于它们制备的工艺和中间体。
• [EN] TARGETED THERAPEUTICS<br/>[FR] THÉRAPEUTIQUE CIBLÉE
  申请人：SYNTA PHARMACEUTICALS CORP

  公开号：WO2015038649A1

  公开（公告）日：2015-03-19

  The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.

  本发明提供了包括与将效应子导向至感兴趣的生物靶点的结合基团共轭的药理化合物。同样，本发明提供了包括这些化合物的组合物、试剂盒和方法（例如治疗、诊断和成像）。这些化合物可以被描述为蛋白质相互作用结合基团-药物共轭（SDC-TRAP）化合物，其中包括蛋白质相互作用结合基团和效应子。例如，在针对治疗癌症的某些实施方式中，SDC-TRAP可以包括Hsp90抑制剂共轭到细胞毒性药剂作为效应子。